VivoSeq
Other

Low Anterior Resection Syndrome

0

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Low Anterior Resection Syndrome is an early-stage landscape with 0 programs across 2 companies. The most active players are HEM Pharma Inc., Simona Ascanelli.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

HEM Pharma Inc.

0 programs

PreclinicalS

Simona Ascanelli

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Recruiting3 · 30%
Unknown status3 · 30%
Completed2 · 20%
Terminated1 · 10%
Not yet recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
Recruiting·OOhio State University Comprehensive Cancer Center·N/A·NCT06424522·80 enrolled
Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome
Recruiting·UUniversity of Aarhus·Phase 3·NCT04087421·114 enrolled
5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)
Recruiting·SSeoul National University Hospital·N/A·NCT05577845·212 enrolled
Evaluating the Optimal Timing of Trans-Anal Irrigation for Low Anterior Resection Syndrome Post-rectal Cancer Surgery - An Italian Multicentre Randomised Study
Not yet recruiting·—·Preclinical·NCT07696689·250 enrolled
The Value of Botox-A for Management of Low Anterior Resection Syndrome
Completed·—·Phase 2·NCT01589471·23 enrolled
Effect of Treatment of Low Anterior Resection Syndrome After Rectal Cancer Surgery
Completed·—·N/A·NCT03215017·45 enrolled
A Prospective Pilot Study to Assess the Efficacy of BOTOX-A in Patients With Low Anterior Resection Syndrome (LARS>20) and Refractory Medical Treatment After Rectal Resection
Terminated·UUniversity Hospital, Bordeaux·Phase 2·NCT04991688·11 enrolled
Anal Dilatation Plus Probiotics Before Ileostomy Reduction for Low Anterior Resection Syndrome
Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT04688242·164 enrolled
HEM1036 Phase 2 Study in Low Anterior Resection Syndrome
Unknown status·HHEM Pharma Inc.·Phase 2·NCT05527301·67 enrolled
The Effect of Melatonin in Patients With Low Anterior Resection Syndrome
Unknown status·—·Phase 2·NCT05042700·21 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)